IRadimed Corporation (IRMD)

IRadimed beat expectations on earnings while revenue was essentially in line, with results for the second fiscal quarter of 2026 reported on July 31, 2026 showing adjusted EPS of $0.46 topping the $0.44 estimate (+4.5%) on revenue of $20.5 million versus a $20.4 million estimate (+0.6%, in line). Revenue rose 0.3% to roughly $20.5 million from about $20.4 million a year ago, while profitability ran at a gross margin of ~74% and an operating margin of ~31%, with gross profit of about $15.2 million and operating income of roughly $6.4 million. Net income fell 9.6% year over year to about $5.2 million, down from roughly $5.8 million, and adjusted EPS declined 6.1% from $0.49 a year ago despite the consensus beat. The company generated operating cash flow of about $5.9 million and paid roughly $2.6 million in dividends during the quarter. For the next period, consensus calls for EPS of $0.52 on revenue of $23.2 million.